Respiratory syncytial virus (RSV) isn’t following a typical seasonal pattern this year and pediatric practices are responding accordingly.
According to the American Academy of Pediatrics (AAP), most states have extended the RSV immunization season for eligible infants and toddlers through the end of April 2026 due to ongoing virus circulation and higher-than-usual positivity rates.
Why the RSV Season Was Extended
RSV peaked later than expected, with federal data showing 7.5% test positivity in late March, compared to 5% at the same time last year. Health officials report that pediatric hospitalizations and emergency visits related to RSV have continued into early spring, prompting state immunization programs to reassess their timelines.
Association of Immunization Managers (AIM) reports that 48 jurisdictions are extending RSV immunization access through April 30, while others are offering mid-month reassessments or case-by-case administration. These decisions are being guided by local surveillance data and the goal of reducing severe RSV outcomes.
AAP Recommendations Remain the Same
The AAP continues to recommend RSV prevention using monoclonal antibodies for:
- Infants under 8 months entering their first RSV season
- Children 8–19 months who are at high risk and entering their second season
These immunizations are designed to significantly reduce RSV-related hospitalizations, particularly among infants, who remain the most vulnerable to severe illness.
What This Means for Practices
- RSV immunization may continue through April in most states
- Providers should follow state-specific guidance and eligibility criteria
- Extended access offers added flexibility to protect patients during prolonged RSV activity
CPP Buying Group will continue sharing timely updates to help pediatric practices stay informed, prepared, and supported as RSV patterns evolve. Contact CPP if you have any questions. We’re here to support your practice’s immunization program so that together, we can improve the health of generations to come.
